Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep 1;36(11):1613-1615.
doi: 10.1097/QAD.0000000000003306.

Vertical anti-SARS-CoV-2 monoclonal antibody transfer from mothers to HIV-exposed and unexposed infants

Robin Kobbe  1 , Ulf Schulze-Sturm  2 , Pelin Kurnaz  2 , Cornelius Rau  2 , Ann-Christin Tallarek  3 , Marc Lütgehetmann  4 , Sabine Jordan  5 , Stefan Schmiedel  5
Affiliations
Comment

Vertical anti-SARS-CoV-2 monoclonal antibody transfer from mothers to HIV-exposed and unexposed infants

Robin Kobbe et al. AIDS. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Montejano R, Marcelo C, Falces-Romero I, Del Valle LG, De Soto T, Garcia-Rodríguez J, Arribas JR. Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV . AIDS 2022; 36:751–753.
    1. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/ . [Accessed 29 December 2021].
    1. Mayer C, VanHise K, Caskey R, Naqvi M, Burwick RM. Monoclonal antibodies casirivimab and imdevimab in pregnancy for coronavirus disease 2019 (COVID-19) . Obstet Gynecol 2021; 138:937–939.
    1. Hirshberg JS, Cooke E, Oakes MC, Odibo AO, Raghuraman N, Kelly JC. Monoclonal antibody treatment of symptomatic COVID-19 in pregnancy: initial report . Am J Obstet Gynecol 2021; 225:688–689.
    1. RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial . Lancet 2022; 399:665–676.